MK-8835/PF-04971729 vs. Placebo in T2DM Subjects with Stage 3 Chronic

• Research type

  Research Study

• Full title

  A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) in Subjects with Type 2 Diabetes Mellitus with Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Background Antihyperglycemic Therapy

• IRAS ID

  145554

• Contact name

  Martin Gibson

• Contact email

  martin.gibson@manchester.ac.uk

• Sponsor organisation

  Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

• Eudract number

  2013-003587-31

• Clinicaltrials.gov Identifier

  NCT01986855

• REC name

  East Midlands - Nottingham 2 Research Ethics Committee

• REC reference

  14/EM/0073

• Date of REC Opinion

  3 Apr 2014

• REC opinion

  Further Information Favourable Opinion